Cargando…
Targeting Anti-Angiogenic VEGF(165)b–VEGFR1 Signaling Promotes Nitric Oxide Independent Therapeutic Angiogenesis in Preclinical Peripheral Artery Disease Models
Nitric oxide (NO) is the critical regulator of VEGFR2-induced angiogenesis. Neither VEGF-A over-expression nor L-Arginine (NO-precursor) supplementation has been effective in helping patients with Peripheral Artery Disease (PAD) in clinical trials. One incompletely studied reason may be due to the p...
Autores principales: | Kuppuswamy, Sivaraman, Annex, Brian H., Ganta, Vijay C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454804/ https://www.ncbi.nlm.nih.gov/pubmed/36078086 http://dx.doi.org/10.3390/cells11172676 |
Ejemplares similares
-
Inhibiting Anti-angiogenic VEGF165b Activates a Novel miR-17-20a-Calcipressin-3 Pathway that Revascularizes Ischemic Muscle in Peripheral Artery Disease
por: Batan, S, et al.
Publicado: (2023) -
Systems Pharmacology of VEGF165b in Peripheral Artery Disease
por: Clegg, Lindsay E., et al.
Publicado: (2017) -
A multiscale computational model predicts distribution of anti-angiogenic isoform VEGF(165b) in peripheral arterial disease in human and mouse
por: Chu, Liang-Hui, et al.
Publicado: (2016) -
Inhibition of VEGF(165)/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis
por: Chen, Chi-Kuan, et al.
Publicado: (2016) -
VEGF(121)b and VEGF(165)b are weakly angiogenic isoforms of VEGF-A
por: Catena, Raúl, et al.
Publicado: (2010)